Total Payments
$1.5M
2024 Payments
$258,961
Companies
40
Transactions
2,926
Medicare Patients
9,835
Medicare Billing
$615,646
Payment Breakdown by Category
Other$1.1M (75.1%)
Travel$228,270 (15.4%)
Consulting$84,442 (5.7%)
Food & Beverage$57,029 (3.8%)
Education$570.95 (0.0%)
Research$63.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 510 | 74.4% |
| Travel and Lodging | $228,270 | 832 | 15.4% |
| Consulting Fee | $84,442 | 32 | 5.7% |
| Food and Beverage | $57,029 | 1,525 | 3.8% |
| Honoraria | $7,658 | 5 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,000 | 1 | 0.2% |
| Education | $570.95 | 20 | 0.0% |
| Unspecified | $63.56 | 1 | 0.0% |
Payments by Type
General
$1.5M
2,925 transactions
Research
$63.56
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $341,891 | 572 | $0 (2024) |
| ABBVIE INC. | $266,135 | 532 | $0 (2024) |
| PFIZER INC. | $152,165 | 282 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $131,146 | 250 | $0 (2024) |
| Lilly USA, LLC | $121,103 | 199 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $91,417 | 183 | $0 (2024) |
| Celgene Corporation | $82,665 | 145 | $0 (2019) |
| Amgen Inc. | $75,154 | 134 | $0 (2024) |
| Incyte Corporation | $74,138 | 149 | $0 (2024) |
| GENZYME CORPORATION | $62,029 | 90 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $258,961 | 460 | UCB, Inc. ($120,089) |
| 2023 | $225,879 | 388 | Lilly USA, LLC ($69,629) |
| 2022 | $188,412 | 377 | ABBVIE INC. ($52,723) |
| 2021 | $75,370 | 140 | UCB, Inc. ($23,505) |
| 2020 | $82,117 | 152 | UCB, Inc. ($30,815) |
| 2019 | $305,298 | 608 | UCB, Inc. ($95,937) |
| 2018 | $208,887 | 420 | PFIZER INC. ($53,866) |
| 2017 | $141,559 | 381 | AbbVie, Inc. ($40,219) |
All Payment Transactions
2,926 individual payment records from CMS Open Payments — Page 1 of 118
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $38.86 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $9.09 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,336.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $26.56 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $21.88 | General |
| Category: Immunology | ||||||
| 12/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $5.74 | General |
| 12/13/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological), Winlevi | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $28.83 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Education | In-kind items and services | $8.45 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,500.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,000.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,006.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $286.76 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $43.70 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $24.19 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $23.45 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $21.66 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Immunology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 2,459 | 4,999 | $382,740 | $154,867 |
| 2022 | 21 | 2,710 | 5,480 | $465,825 | $179,651 |
| 2021 | 18 | 2,279 | 3,702 | $341,019 | $136,177 |
| 2020 | 19 | 2,387 | 4,424 | $780,068 | $144,951 |
Total Patients
9,835
Total Services
18,605
Medicare Billing
$615,646
Procedure Codes
74
All Medicare Procedures & Services
74 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 758 | 1,102 | $140,753 | $61,360 | 43.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 304 | 348 | $54,983 | $25,530 | 46.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 451 | 613 | $59,294 | $21,387 | 36.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 356 | 2,166 | $35,090 | $9,980 | 28.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 155 | 172 | $24,428 | $9,687 | 39.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 131 | 131 | $20,604 | $8,143 | 39.5% |
| 12031 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | Office | 2023 | 30 | 31 | $11,435 | $5,424 | 47.4% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 13 | 13 | $5,523 | $2,881 | 52.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 28 | $5,058 | $2,357 | 46.6% |
| 11601 | Removal of cancer skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 21 | 22 | $7,049 | $2,042 | 29.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 71 | 96 | $9,696 | $2,008 | 20.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 49 | 54 | $4,295 | $1,986 | 46.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 12 | 12 | $2,101 | $932.60 | 44.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 12 | 15 | $1,061 | $547.69 | 51.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 34 | 50 | $1,075 | $487.60 | 45.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 36 | 146 | $295.23 | $115.01 | 39.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 666 | 1,064 | $130,340 | $58,596 | 45.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 288 | 339 | $52,839 | $23,456 | 44.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 448 | 629 | $63,529 | $21,138 | 33.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 181 | 208 | $28,797 | $12,241 | 42.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 194 | 194 | $28,858 | $11,846 | 41.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 346 | 2,124 | $53,100 | $9,842 | 18.5% |
| 12031 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | Office | 2022 | 49 | 51 | $17,452 | $9,243 | 53.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 220 | 368 | $35,672 | $8,553 | 24.0% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 11 | 16 | $7,200 | $4,859 | 67.5% |
About Dr. Kimberly Vincent, M.D
Dr. Kimberly Vincent, M.D is a Specialist healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548339369.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kimberly Vincent, M.D has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $258,961 received in 2024. These payments were reported across 2,926 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
As a Medicare-enrolled provider, Vincent has provided services to 9,835 Medicare beneficiaries, totaling 18,605 services with total Medicare billing of $615,646. Data is available for 4 years (2020–2023), covering 74 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Nashville, TN
- Active Since 11/07/2006
- Last Updated 05/10/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1548339369
Products in Payments
- Cimzia (Drug) $166,073
- Otezla (Drug) $154,396
- DUPIXENT (Biological) $128,358
- Bimzelx (Biological) $120,132
- EUCRISA (Drug) $104,749
- TALTZ (Drug) $89,312
- Humira (Biological) $84,688
- COSENTYX (Biological) $79,840
- OPZELURA (Drug) $74,066
- SKYRIZI (Biological) $63,244
- RINVOQ (Biological) $60,012
- CIBINQO (Drug) $46,152
- DUPIXENT (Drug) $31,775
- DUPIXENT DUPILUMAB INJECTION (Biological) $28,677
- HUMIRA (Biological) $22,026
- ORACEA (Drug) $13,770
- Skyrizi (Biological) $12,808
- SOOLANTRA (Drug) $7,864
- Sitavig (Drug) $7,229
- Sotyktu (Drug) $4,914
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Nashville
Dr. Brian Biesman, M.d, M.D
Specialist — Payments: $1.4M
Specialist $1.4M
Dr. Michael Gold, M.d, M.D
Specialist — Payments: $937,123
Specialist $937,123
Ms. Andrea Hayes, M.d, M.D
Specialist — Payments: $429,136
Specialist $429,136
Dr. Pat Whitworth, Md, MD
Specialist — Payments: $112,766
Specialist $112,766
Michael Stabile, M.d, M.D
Specialist — Payments: $43,099
Specialist $43,099
Dr. Thomas Davis, M.d, M.D
Specialist — Payments: $42,692
Specialist $42,692